This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.

Disclosed herein include circuits, compositions, nucleic acids, populations, systems, and methods enabling cells to sense, control, and/or respond to their own population size. In some embodiments, an orthogonal communication channel allows specific communication between engineered cells. Also described herein, in some embodiments, is an evolutionarily robust ‘paradoxical’ regulatory circuit architecture in which orthogonal signals both stimulate and inhibit net cell growth at different signal concentrations. In some embodiments, engineered cells autonomously reach designed densities and/or activate therapeutic or safety programs at specific density thresholds. Methods of treatment are also provided in some embodiments.

The disclosure relates methods for increasing the efficiency of cellular reprogramming of somatic cells and improving the maturity of the resulting cells.

Provided are methods for producing a population of cells enriched with non-activated/non-mature cells, in particular non-activated/non-mature T and/or B cells, optionally genetically modified T and/or B cells. The method includes contacting a heterogeneous population of mammalian cells with an apoptosis inducing ligand, wherein said contacting induces apoptosis of active/mature cells while non active/mature cells remain resistant to the apoptotic signal. Further provided are therapeutic uses of the enriched cell populations.

The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR α chain, TCR β chain, beta-2 microglobulin and FAS further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.

Method for the production of bi-functional cells comprising engineering a starting cell population with a phenotype attributable to human pericytes extracted from adipose tissue (AD-PC), obtaining engineered cells, known as bi-functional AD-PCs, expressing (which means that they produce) simultaneously both the anti-tumor molecule TRAIL and also the truncated form of a chimeric receptor targeted against the GD2 antigen (GD2 tCAR); this dual targeting (understood as reaching a specific target), based on affinity and mediated by both TRAIL and also GD2 tCAR, supports the prediction of combining site-specificity with a prolonged retention of AD-PCs in tumors expressing the antigen GD2, so as to achieve a more effective release of TRAIL for still incurable tumors.

To enable stable supply of differentiated T cells, the present invention provides a method for producing, or a method for expansion culture, or a kit for expansion culture of a CD3-positive cell in which T cell marker CD3 is expressed on the cell membrane.

The present invention relates to interleukin-4 receptor binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 receptor binding protein moiety joined to a pro-apoptotic Bcl-2 family member protein moiety.

This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.

Inducible engineered tissue constructs comprising at least one cell population comprising a genetic construct are provided. Methods of making and using said constructs are also provided.